ICER Releases Two Draft Reports on Obeticholic Acid

The Institute for Clinical and Economic Review (ICER) recently released two Draft Evidence Reports assessing the comparative clinical effectiveness and value of obeticholic acid. Learn more about its use for primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) here. (Source: ICER, 5/25/16)

You might also be interested in:

NASH Drugs Could Face Payer Roadblocks May 18, 2019
ICER Using New Economic Modeling Platform for Value Assessment August 24, 2018
Review of Influence: The Institute for Clinical and Economic Review February 26, 2019
ICER Releases Report on Antiandrogen Therapies for… August 25, 2018
ICER Releases Draft Scoping Document for Peanut Allergy Treatments November 22, 2018
ICER Seeks Nominations for Independent Review Groups December 6, 2018
ICER Releases Report on Inotersen, Patisiran July 21, 2018